MCRB Logo

Seres Therapeutics, Inc. (MCRB) 

NASDAQ
Market Cap
$129.54M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
617 of 776
Rank in Industry
333 of 433

Largest Insider Buys in Sector

MCRB Stock Price History Chart

MCRB Stock Performance

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal …

Insider Activity of Seres Therapeutics, Inc.

Over the last 12 months, insiders at Seres Therapeutics, Inc. have bought $0 and sold $95,088 worth of Seres Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Seres Therapeutics, Inc. have bought $9.18M and sold $542,781 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,912,748 shares for transaction amount of $9.18M was made by AFEYAN NOUBAR () on 2022‑07‑05.

List of Insider Buy and Sell Transactions, Seres Therapeutics, Inc.

2024-10-28SaleCEO and President
8,748
0.0045%
$0.69$6,0370.00%
2024-10-28SaleChief Legal Officer and EVP
4,259
0.0022%
$0.69$2,9390.00%
2024-10-28SaleSee Remarks
2,983
0.0015%
$0.69$2,0590.00%
2024-10-28SaleSee Remarks
3,984
0.0021%
$0.69$2,7490.00%
2024-10-28SaleSee Remarks
4,334
0.0022%
$0.69$2,9910.00%
2024-08-16SaleCEO and President
2,518
0.0015%
$0.84$2,1150.00%
2024-08-16SaleChief Legal Officer and EVP
873
0.0005%
$0.84$7330.00%
2024-08-16SaleSee Remarks
728
0.0004%
$0.84$6120.00%
2024-08-16SaleSee Remarks
1,128
0.0007%
$0.84$9480.00%
2024-08-16SaleSee Remarks
923
0.0006%
$0.84$7750.00%
2024-08-16SaleSee Remarks
973
0.0006%
$0.84$8170.00%
2024-08-05SaleSee Remarks
24,480
0.0137%
$1.08$26,534-32.73%
2024-05-15SaleCEO and President
2,435
0.0016%
$0.94$2,289-6.54%
2024-05-15SaleChief Legal Officer and EVP
843
0.0005%
$0.94$792-6.54%
2024-05-15SaleSee Remarks
1,090
0.0007%
$0.94$1,025-6.54%
2024-05-15SaleSee Remarks
891
0.0006%
$0.94$838-6.54%
2024-05-15SaleSee Remarks
939
0.0006%
$0.94$883-6.54%
2024-05-15SaleSee Remarks
703
0.0005%
$0.94$661-6.54%
2024-02-16SaleChief Financial Officer
3,939
0.0031%
$1.08$4,254-17.08%
2024-02-16SaleCEO and President
11,549
0.0092%
$1.08$12,473-17.08%

Insider Historical Profitability

40%
AFEYAN NOUBAR
5875711
3.4522%
$0.7621+40%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Flagship Pioneering$17.89M15.2623.12M0%+$01.17
Fidelity Investments$17.53M14.9622.65M+16.83%+$2.53M<0.01
BlackRock$5.28M4.516.83M-7%-$397,929.95<0.0001
The Vanguard Group$5.21M4.456.73M+12.15%+$564,716.79<0.0001
Hudson Bay Capital Management LP$4.2M3.585.42M+25.57%+$855,070.960.03
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.